Sagin Capital & Consulting

代表取締役 (Representative Director) Naoto Shimoeda oversees investment decisions. The firm’s small structure and bank-subsidiary status suggest a concentrated decision process with Shimoeda as the key principal, though the firm does not list additional investment committee members publicly.

Sagin Capital & Consulting is a wholly owned subsidiary of Saga Bank, a regional Japanese bank headquartered in Saga Prefecture. Established in 1991, the firm operates as the bank’s primary vehicle for direct venture and growth-stage investments and, since November 2021, also provides financial-product intermediation services to the bank’s clients.

The firm covers venture-stage startups and growth-stage companies, with a focus on new business development and business succession. Its portfolio includes early-stage biotech (Serv BioPharma, Arktus Therapeutics), a food-business succession roll-up (Manfuku Holdings), and a luxury resale service (KLD). It also operates a 'Support Fund' for smaller or earlier-stage companies such as SA-GA and Shashusho Inc.

No. The firm does not publish AUM or aggregate deployment figures. Its ¥80 million stated capital base is statutory paid-in capital for the corporate entity, not a measure of managed assets. The firm’s investment scale is therefore not publicly verifiable.

All confirmed portfolio companies — Arktus Therapeutics, ExtenD, Serv BioPharma, Manfuku Holdings, KLD, SA-GA, and Shashusho Inc. — are Japan-domiciled. The firm’s mandate and parent-bank geography strongly concentrate investment within Japan, particularly in the Kyushu region.